Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required

Value in Health

Volumn 18, Issue 6, 2015, Pages 865-875

  McKenna, Claire ^a   Soares, Marta ^a   Claxton, Karl ^a   Bojke, Laura ^a   Griffin, Susan ^a   Palmer, Stephen ^a   Spackman, Eldon ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

cost effectiveness; coverage with evidence development; health technology assessment; only in research; reimbursement decisions; research decisions

Indexed keywords

CLOPIDOGREL; ANTITHROMBOCYTIC AGENT;

ARTICLE; CHECKLIST; CHRONIC DISEASE; CHRONIC STABLE ANGINA; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COUNTERPULSATION; ENHANCED EXTERNAL COUNTERPULSATION; HEALTH CARE COST; HEALTH STATUS; HUMAN; INVESTMENT; IRRECOVERABLE COST; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NET HEALTH EFFECT; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SEVEN POINT CHECKLIST; STABLE ANGINA PECTORIS; TREATMENT DURATION; ACUTE CORONARY SYNDROME; ANGINA, STABLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG COST; ECONOMICS; HEALTH SERVICES RESEARCH; NATIONAL HEALTH SERVICE; STANDARDS; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNCERTAINTY;

ACUTE CORONARY SYNDROME; ANGINA, STABLE; BIOMEDICAL RESEARCH; CHECKLIST; CHOICE BEHAVIOR; COST-BENEFIT ANALYSIS; COUNTERPULSATION; DRUG COSTS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH SERVICES RESEARCH; HUMANS; JUDGMENT; MODELS, ECONOMIC; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TIME FACTORS; TREATMENT OUTCOME; UNCERTAINTY;

EID: 84942296878     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2015.05.003     Document Type: Article

References (28)

1. K. Claxton The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies J Health Econ 18 1999 342 364
2. K. Claxton, J. Cohen, and P. Neumann When is evidence sufficient? Health Aff 24 2005 93 101
3. K. Claxton, M. Sculpher, and M. Drummond A rational framework for decision making by the National Institute for Clinical Excellence Lancet 360 2002 711 715
4. S.C. Griffin, K.P. Claxton, S.J. Palmer, and M.J. Sculpher Dangerous omissions: the consequences of ignoring decision uncertainty Health Econ 20 2011 212 224
5. P. Trueman, D.L. Grainger, and K.E. Downs Coverage with evidence development: applications and issues Int J Technol Assess Health Care 26 2010 79 85
6. Z. Philips, K. Claxton, and S. Palmer The half-life of truth: what are appropriate time horizons for research decisions? Med Decis Making 28 2008 287 299
7. S. Eckermann, and A. Willan Time and expected value of sample information wait for no patient Value Health 11 2008 522 526
8. S. Eckermann, and A.R. Willan The option value of delay in health technology assessment Med Decis Making 28 2008 300 305
9. C. McKenna, and K. Claxton Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis Med Decis Making 31 2011 853 865
10. K. Claxton, S. Palmer, L. Longworth, and et al. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development Health Technol Assess 16 2012 1 323
11. C. Main, S. Palmer, S. Griffin, and et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment elevation acute coronary syndromes: a systematic review and economic evaluation Health Technol Assess 8 2004 1 141
12. C. McKenna, C. McDaid, S. Suekarran, and et al. Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis Health Technol Assess 13 2009 iii-iv, ix-xi, 1-90
13. W. Rogowski, J. Burch, S. Palmer, and et al. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis Health Technol Assess 13 2009 1 77
14. TA80: Clopidogrel in the Treatment of Non-ST-Segment-Elevation Acute Coronary Syndrome. London: National Institute for Health and Clinical Excellence, 2004.
15. CG94: Unstable Angina and NSTEMI: The Early Management of Unstable Angina and Non-ST-Segment-Elevation Myocardial Infarction. London: National Institute for Health and Clinical Excellence, 2010.
16. Claxton K, Palmer S, Longworth L, et al. Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health technologies. Centre for Health Economics, University of York, CHE Research Paper 69, 2011.
17. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence, 2008.
18. S. Allender, V. Peto, P. Scarborough, and et al. Morbidity: Coronary Heart Disease Statistics 15th ed 2007 British Heart Foundation London
19. Claxton K, Eggington S, Ginnelly L, et al. A pilot study of value of information analysis to support research recommendations for the National Institute for Clinical Excellence. Centre for Health Economics, York, Research Paper 4, 2005.
20. K. Claxton, and M. Sculpher Using value of information analysis to prioritise health research: some lessons from recent UK experience Pharmacoeconomics 24 2006 1055 1068
21. Centers for Medicare & Medicaid Services Medicare and Medicaid programs: conditions for coverage for organ procurement organizations (OPOs) Final rule. Fed Reg 31 2006 30981 31054
22. K. Chalkidou, A. Hoy, and P. Littlejohns Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research J Royal Soc Med 100 2007 453 460
23. J.J. Carlson, S.D. Sullivan, L.P. Garrison, and et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers Health Policy 96 2010 179 190
24. C.J. McCabe, T. Stafinski, R. Edlin, and D. Menon Access with evidence development schemes: a framework for description and evaluation Pharmacoeconomics 28 2010 143 152
25. T. Stafinski, C.J. McCabe, and D. Menon Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems Pharmacoeconomics 28 2010 113 142
26. A. Towse, and L.P. Garrison Jr Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products Pharmacoeconomics 28 2010 93 102
27. J. Carlson, S. Sullivan, L. Garrison, and et al. Linking payment and health outcomes: a systematic review of performance-based health 2008 University of Washington Washington
28. K. Claxton, S. Griffin, H. Koffijberg, and C M Expected health benefits of additional evidence: principles, methods and applications Centre for Health Economics, University of York, CHE Research Paper 83 2013